Metric Snapshot
- Latest value
- 5.5%
- Coverage range
- 31 Dec 2020 - 31 Dec 2025
- Fact rows
- 19
Shareable Research Card
APLS - Apellis Pharmaceuticals, Inc. Operating Margin
This metric view shows APLS - Apellis Pharmaceuticals, Inc. operating margin history from SEC company facts.
Use it to verify the latest reported value, compare nearby periods, and jump to a cross-company ranking when a curated insight exists.
- Context
- Latest reported period: Q4 2025
- Latest reported value
- 5.5%
Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Values may differ by reporting period and company taxonomy.
Financial Metric Page
Apellis Pharmaceuticals, Inc.: Operating Margin
Latest period: Q4 2025. Period end: 31 Dec 2025. Units: %. Frequency: quarterly and annual.
The operating margin measures the profit a company makes on a dollar of sales after accounting for the direct costs involved in earning those revenues.
What This Metric Tells You
- Shows the reported level of operating margin over 31 Dec 2020 - 31 Dec 2025.
- Use consecutive periods in the table to assess trend direction when YoY change is unavailable.
- Built from 19 SEC fact rows for this metric and issuer.
How To Read This Chart
- Start with the latest point, then compare it with the prior periods to see direction.
- Use quarterly sequence to compare like-for-like periods.
- Use YoY change bars to separate growth from contraction across matching periods.
Official SEC Source
Source: SEC Company Facts
Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Reporting periods may differ by company.
Compare This Metric Across Companies
Compare latest available Operating Margin levels across SEC-reporting companies, then open each company metric page for SEC-backed verification. Reporting periods may differ by company.
| Rank | Company | Latest value | Reported period | Next step |
|---|---|---|---|---|
| 1 | Global Warming Solutions, Inc. (["gwso"]) | 99905400% | Quarter - 30 Sep 2022 | Open Global Warming Solutions, Inc. Operating Margin |
| 2 | NAMI Corp. ([]) | 1080289% | Quarter - 31 Mar 2021 | Open NAMI Corp. Operating Margin |
| 3 | PharmaCyte Biotech, Inc. (["pmcb"]) | 396584% | Quarter - 31 Jan 2014 | Open PharmaCyte Biotech, Inc. Operating Margin |
| 4 | ALR Technologies SG Ltd. (["alrtf"]) | 180380% | Year - 31 Dec 2022 | Open ALR Technologies SG Ltd. Operating Margin |
| 5 | MUSTANG BIO, INC. (["mbio"]) | 83624% | Quarter - 30 Sep 2019 | Open MUSTANG BIO, INC. Operating Margin |
| 6 | DOMINION ENERGY SOUTH CAROLINA, INC. ([]) | 63100% | Year - 31 Dec 2020 | Open DOMINION ENERGY SOUTH CAROLINA, INC. Operating Margin |
Metric Details
- Metric
- Operating Margin (OperatingMargin)
- Taxonomy
- ratio
- Units tracked
- %
- Frequency coverage
- quarterly and annual
- History range
- 31 Dec 2020 - 31 Dec 2025
- Facts on this page
- 19
- Description
- The operating margin measures the profit a company makes on a dollar of sales after accounting for the direct costs involved in earning those revenues.
- Metric-level SEC endpoint
- Open SEC company concept
Chart Context
Compare periods with the same frequency first, then use YoY and TTM series to confirm whether changes are structural or one-off.
Operating Margin, Quarterly (%)
Operating Margin, YoY Quarterly Change (%)
Operating Margin, Annual (%)
Operating Margin, YoY Annual Change (%)
Apellis Pharmaceuticals, Inc. Quarterly Operating Margin (%)
| Period | Value | YoY Chg | Change % | Start Date | End Date |
|---|---|---|---|---|---|
| Q4 2025 | 5.5% | +27% | 01 Oct 2025 | 31 Dec 2025 | |
| Q3 2025 | 7.9% | +39% | 01 Jul 2025 | 30 Sep 2025 | |
| Q2 2025 | -25% | +25% | +49% | 01 Apr 2025 | 30 Jun 2025 |
| Q1 2025 | -24% | +53% | +69% | 01 Jan 2025 | 31 Mar 2025 |
| Q4 2024 | -21% | +109% | +84% | 01 Oct 2024 | 31 Dec 2024 |
| Q3 2024 | -31% | +187% | +86% | 01 Jul 2024 | 30 Sep 2024 |
| Q2 2024 | -50% | +282% | +85% | 01 Apr 2024 | 30 Jun 2024 |
| Q1 2024 | -77% | +528% | +87% | 01 Jan 2024 | 31 Mar 2024 |
| Q4 2023 | -130% | +658% | +83% | 01 Oct 2023 | 31 Dec 2023 |
| Q3 2023 | -219% | 01 Jul 2023 | 30 Sep 2023 | ||
| Q2 2023 | -332% | 01 Apr 2023 | 30 Jun 2023 | ||
| Q1 2023 | -605% | 01 Jan 2023 | 31 Mar 2023 | ||
| Q4 2022 | -788% | 01 Oct 2022 | 31 Dec 2022 |
Apellis Pharmaceuticals, Inc. Annual Operating Margin (%)
| Period | Value | YoY Chg | Change % | Start Date | End Date |
|---|---|---|---|---|---|
| 2025 | 5.5% | +27% | 01 Jan 2025 | 31 Dec 2025 | |
| 2024 | -21% | +109% | +84% | 01 Jan 2024 | 31 Dec 2024 |
| 2023 | -130% | +658% | +83% | 01 Jan 2023 | 31 Dec 2023 |
| 2022 | -788% | +17% | +2.1% | 01 Jan 2022 | 31 Dec 2022 |
| 2021 | -806% | -720% | -845% | 01 Jan 2021 | 31 Dec 2021 |
| 2020 | -85% | 01 Jan 2020 | 31 Dec 2020 |
* An asterisk sign (*) next to the value indicates that the value is likely invalid.